Status:
COMPLETED
Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Hepatic Fibrogenesis
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine the effect of moderate alcohol intake on liver disease caused by HCV in terms of speed of progression as compared to those not drinking alcohol.
Eligibility Criteria
Inclusion
- Outpatient with HCV who is not receiving or planning treatment but is receiving standard of care monitoring every 3 months and is either abstinent from alcohol or drinking only moderately
Exclusion
- HIV co-infection
- Treated within the past 6 months
- History (hx) of other liver disease
- Alcohol use greater than 30 g/day or history of binge drinking in the last year
- Decompensated liver disease
Key Trial Info
Start Date :
August 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00205075
Start Date
August 1 2004
End Date
June 1 2008
Last Update
December 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792